

Programme for Inclusion of Active Substances in Annex I to Council Directive 98/8/EC



Amines, N-C10–C16-alkyltrimethylenedi-, reaction products with chloroacetic acid; Ampholyt (PT 2, 3, 4)

CAS-No. 139734-65-9

DOCUMENT IIIA (A5)

Evaluation Report

Rapporteur: Ireland

April 2015

Ampholyt (PT2, 3, 4)

Document A5

CONTENTS

Section A5	Effectiveness against target organisms and intended	
Annex Point IIA5	uses	
		Official use only
Function	Reference A5.1/01:	
(IIA5.1)	Anonymous (2000): Ampholyt 20 – Function (Benefit/Usefullness) Goldschmidt GmbH, Essen, February, 28 th , 2000 (unpublished).	
	Disinfectant: PT 2, 3, 4	
	bactericide, fungicide, limited virucide	
Organism(s) to be controlled and products, organisms or objects to be protected (IIA5.2)		
Organism(s) to be controlled	Bacteria, fungi, viruses contaminating surfaces, floors, walls or other working areas.	
Products, organisms or objects to be protected	Humans and animals at risk of exposure to germs (communicable diseases) in public areas (e.g. hospitals, spas, swimming baths, etc.; product type 2), animal housings or transport means (product type 3), and in the food processing industry (product type 4).	
	The treated objects are thus pre-cleaned walls, floors, work surfaces, conveyors, pipelines and equipment in the above areas, as appropriate.	
Effects on target organisms, and likely concentration at which the active substance will be used (IIA5.3)		
Effects on target organisms	Ampholyt 20 is an amphotheric surfactant, reducing the number of viable bacterial or fungal cells and reproductive viruses.	
Likely concentrations at which the A.S. will be used	Aqueous solutions of 0.5–1% Ampholyt 20 (=TEGO 2000), corresponding to $0.1-0.2$ % a.i. final concentration.	

հոհ oti • st t .t . d int Tree

Section A5 Effectiveness against target organisms and intended							
Annex Point IIA5	uses	1					
		Official use only					
Mode of action (including	Reference A5.4/01:						
time delay) (IIA5.4)	Anonymous (undated): Mechanism of Killing Microorganisms. Goldschmidt GmbH, Essen, undated (unpublished).						
Mode of action	Ampholyt 20 is an amphotheric surfactant, reducing the number of viable bacterial or fungal cells and reproductive viruses by alteration of the electrochemical charge while integrating/penetrating into the cell/ viral envelope. This results in changes in permeability and irreversible alteration of the structure of the cellular membrane or viral envelope, respectively.						
	The reference elucidates the mode of action of amphoterics in general with an amphoteric disinfectant termed TEGO 51. The adverse effects of amphoterics described in the study, relay on the active amphoteric substances, which justifies the read-across of effects from TEGO 51 to Ampholyt 20. Further, the composition of the amphoteric disinfectant product TEGO 51 is a mixture of Ampholyt 20, plus additional other components, being similar in molecular structure.						
Time delay	No time delay, since the microbicidal effect is immediate. However, a certain residence time needs to be allowed for, in order to ensure sufficient reduction of germ numbers.						
	Residence times are given as 15 to 30 min and up to 2 h depending on kind of contamination (target) and level of pollution of the area. The residence time for bacteria and fungi (1% TEGO 2000) is determined to be 30 minutes for dirty conditions at room temperature, 60 minutes at 10 °C. The mandatory residence time for the requested efficacy against viruses depends as well on the target viruses, for example for HBV, 1% of TEGO 2000 requires 60 min, for the reduction of Herpes simplex virus contamination 15 minutes with 0.75% Ampholyt 20 is sufficient. For more details please refer to Section B5.10.2.						
Field of use envisaged (IIA5.5)							
MG01: Disinfectants, general biocidal	PT 02: Private area and public health area disinfectants and other biocidal products PT 03: Veterinary hygiene biocidal products						
products	PT 04: Food and feed area disinfectants						
MG02: Preservatives	_						
MG03: Pest control	_						
MG04: Other biocidal products	_						
Further specifications	_						
User (IIA5.6)	Users of the disinfectant are (i) professional cleaners and (ii) professionals of medical health, foodstuff manufacturing industry, or other industry that needs disinfection of surfaces.						

4

Section A5	Effectiveness against target organisms and intended
Annex Point IIA5	uses

		Official use only
Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies (IIA5.7)		
Development of resistance	Specific resistance to Ampholyt 20 has not become known to date. Resistance to amphoteric disinfectants is not expected due to the relatively unspecific mode of action of amphoterics, which is at least partly based on surface activity. Amphoteric surfactants integrate into the cell wall of bacteria (or the envelope of viruses) and thereby cause leakage of intracellular components in bacteria. Furthermore, the intended uses, including performance of mechanical cleaning procedures hinder the formation of biofilms, thereby additionally reducing the likelihood of development of resistance.	
	Having said that, bacteria or other micro-organisms may generally have an intrinsic or natural capacity of developing resistance to basically any antimicrobial agent. Resistance may in principle also be acquired by adaptation.	
	Resistance may be mediated by resistance genes, which insert in specific sequences or by acquisition of plasmids or transposons, encoding a mechanism to disable a specific antimicrobial action. Microbial resistance to antimicrobial agents – or more generally biocides – is favoured by frequent use of sublethal concentrations and misuse of the agents which imposes a selective pressure.	
	However, since the mode of action of amphoteric surfactants is relatively unspecific, including (as the name implies) surface activity, selection for specific resistance genes is hardly conceivable. Instead, because of the multiply charged character of the molecule, amphotheric agents effectively bind to cellular or viral surfaces, and disrupt the barrier that ensures impermeability. The interaction with membrane components may further disorganise signalling. These effects lead to the very effective decrease in cell viability and viral infectivity. In conclusion, it is therefore considered unlikely that bacteria or viruses develop resistance against Ampholyt 20.	
	Recent literature searches have not revealed any information indicating that resistance to Ampholyt 20 may have occurred.	
	As a general rule, careful working practice, comprising complete and thorough cleaning of the surfaces and objects to be disinfected, may be considered as a suitable means of preventing development of resistance.	
Management strategies	Not applicable, in view of the fact that resistance has to date not been observed.	
	However, as a general strategy, sufficiently efficient concentrations should be applied and the residence times should be considered. In other words: Adherence to the manufacturer's use instructions may be considered as a suitable management strategy.	

Ampholyt	Product-type 2, 3, 4 April 201:					
Section A5 Annex Point IIA5	Effectiveness against target organisms and intended uses					
	388307989C	Official				
		use only				
Likely tonnage to be placed on the market per year	Data on produced/ imported tonnages are considered to be commercially sensitive and are therefore to be treated as CONFIDENTIAL.					
(IIA5.8)	These data are provided separately in Appendix 1 to Document III-A (confidential information).					
	Evaluation by Competent Authorities					
10	Use separate "evaluation boxes" to provide transparency as	2				
	to the comments and views submitted					
	EVALUATION BY RAPPORTEUR MEMBER STATE (*)					
Date	15 th July 2013					
Materials and Methods	Adopt mode of action					
Results and discussion	N/A					
Conclusion	N/A					
Reliability	N/A					
Acceptability	Acceptable					
Remarks	None					
	COMMENTS FROM					
Date						
Materials and Methods						
Results and discussion						
Conclusion						
Reliability						
Acceptability						
Remarks						

Ampholyt	Product-type 2, 3, 4	April 2015
----------	----------------------	------------

Section A5.10.

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
1.0, 0.5 and 0.125 % (v/v) of Ampholyt 20	Pseudomonas aeruginosa, Staphylococcus aureus	Dilution-neutralization method DIN EN 1040	Temperature: $20 \pm 1^{\circ}C$ Contact time: $5 \min \pm 10$ sec	A bacterial viability reduction of more than 10 ⁵ was achieved in both organisms with all of the three concentrations.	B5.10.2/01
0.125, 0.25, and 0.5 % (v/v) of Ampholyt 20	Staphylococcus aureus Enterococcus hirae Escherichia coli Pseudomonas aeruginosa	Quantitative suspension test DIN EN 1276	Temperature: $20 \pm 1^{\circ}C$ Contact time: $5 \min \pm 10$ sec Interfering substance: 0.3 g/L bovine albumin	A bacterial viability reduction of more than 10 ⁵ was achieved in all organisms with all of the three concentrations under clean conditions (0.3 g/L bovine albumin).	B5.10.2/02
0.25, 0.5, and 1.0 % (v/v) of Ampholyt 20	Staphylococcus aureus Enterococcus hirae Escherichia coli Pseudomonas aeruginosa	Quantitative suspension test DIN EN 1276	Temperature: $20 \pm 1^{\circ}C$ Contact time: $5 \min \pm 10$ sec Interfering substance: 0.3 g/L bovine albumin	A bacterial viability reduction of more than 10 ⁵ was achieved in all organisms with all of the three concentrations under clean conditions (0.3 g/L bovine albumin).	B5.10.2/03

Ampholyt	Product-type 2, 3, 4	April 2015
----------	----------------------	------------

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
substance			conditions		
Aspergillus	Candida albicans	Quantitative suspension test	Temperature:	C. albicans viability was reduced within 15 min treatment for	B5.10.2/04
niger: 10, 5	Aspergillus niger	(membrane filtration	$20 \pm 1^{\circ}C$	more than log 4 even with concentrations of 0.25% Ampholyt	
and 2.5 % of		method)	Contact time:	20.	
Ampholyt 20		DIN EN 1650	15 min	A. niger was not affected sufficiently by Ampholyt 20 in	
Candida			exposure time	concentrations up to 10% for 60 min (less than log 4).	
albicans: 1.0,			(C. albicans,		
0.5 and 0.25			A. niger)		
% of			60 min		
Ampholyt 20			exposure time		
			(A. niger)		
			Interfering		
			substance:		
			0.3 g/L		
			bovine		
			albumin		
0.75%	Vaccinia virus strain Elstree	Effectiveness against	Temperature:	A titre reduction of $> 4 \log_{10}$ was achieved in all 3 test samples	B5.10.2/05
Ampholyt 20		viruses (Federal Office of	$20 \pm 1^{\circ}C$	(without, with 0.2% BSA, with 10% FCS) independent of	
		Health and the German	Contact time:	exposure times (5, 10 and 15 min).	
		Association for the Control	5, 10 and		
		of Virus Diseases)	15 min		
			Interfering		
			substance:		
			0.2 % BSA or		
			10.0 % BSA		
0.75%	Bovine viral diarrhea virus	Infectivity was determined	Temperature:	A titre reduction of $> 4 \log_{10}$ was achieved in all 3 test samples	B5.10.2/06
Ampholyt 20	(surrogate of HCV)	by means of end point	$20 \pm 1^{\circ}\mathrm{C}$	(without, with 0.2% BSA, with 10% FCS) after 15 min exposure	
		dilution titration in a micro-	Contact time:	time	
		procedure. The difference	5, 10 and		
		of test titre with the control	15 min		
		is given as reduction factor	Interfering		
		(RF) or $\Delta \log ID_{50}$. The	substance:		
		intectious dose (ID_{50}) was	without, 0.2		
		calculated according to the	% BSA, 10 %		
		method of Spearman	FCS		
		(1908) and Kärber (1931).			

Ampholyt	Product-type 2, 3, 4	April 2015
----------	----------------------	------------

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
substance			conditions		
0.75% Ampholyt 20	Herpes simplex virus, type 1	Infectivity was determined by means of end point dilution titration in a micro- procedure. The difference of test titre with the control is given as reduction factor (RF) or Δ log ID50. The infectious dose (ID50) was calculated according to the method of Spearman (1908) and Kärber (1931). (Quantitative suspension test method, Vero cell cultures were observed for cytopathic effects)	Temperature: 20 ± 1°C Contact time: 5, 10 and 15 min Interfering substance: without, 0.2 % BSA, 10 % FCS	Efficacy of TEGO 2000 (0.75%) on herpes simplex virus is measured by reduction of virucidal effect on Vero cells. The reduction of recommended RF \geq 4.00 is achieved after 5 min with or without interfering substances.	B5.10.2/07
0.75% Ampholyt 20	Bovine coronavirus	Infectivity was determined by means of end point dilution titration in a micro- procedure. The difference of test titre with the control is given as reduction factor (RF) or $\Delta \log ID_{50}$. The infectious dose (ID ₅₀) was calculated according to the method of Spearman (1908) and Kärber (1931).	Temperature: $20 \pm 1^{\circ}C$ Contact time: 5, 10 and 15 min Interfering substance: without, 0.2 % BSA, 10 % FCS	A titre reduction of \geq 4 log ₁₀ was achieved in all test samples (without, with 0.2% BSA, with 10% FCS) already after 5 minutes of exposure.	B5.10.2/08
1.0, 2.0 % Ampholyt 20	Hepatitis B Virus (HBV)	Determination of the modification /destruction of envelope protein HBsAg of HBV by Ampholyt 20	exposure time: 30, 60, and 120 minutes interfering substance: without, 0.2 % BSA, 10 % FCS	Effect of 1% TEGO 2000: After 30 min incubation with 1% TEGO 2000, the HBsAg present in the test system was not detectable any more in the assay without interfering substance (indicating deactivation of HBV). After 60 min HBsAg was also destroyed completely in the assay containing a medium protein concentration, and after 120 min in the assay containing a high protein concentration. Effect of 2% TEGO 2000: After 30 minutes incubation with 2% TEGO 2000 HBsAg was not detectable any more, even in the assay with high protein concentration.	B5.10.2/09

Product-type 2, 3, 4

April 2015

Test	Test organism(s)	Test method	Test	Test r	esults	s: effect	ts, moo	de of a	action,	resista	ance			Reference
substance			conditions											
Serial dilution	Staphylococcus aureus	B5.10.2/10 is a summary	B5.10.2/10 is											B5.10.2/10
of Ampholyt	Streptococcus faecium	report on B5.10.2/11 to	a summary	٨D	°C	indica	ted are	e the u	se con	centrat	ions in	% v/v		
20	Proteus mirabilis	B5.10.2/14	report on	AD	C	slight	ly soile	ed area	ì	highl	y soile	d area		
	Pseudomonas aeruginosa	Qualitative and quantitative	B5.10.2/11 to			bacter	ricidal	fung	icidal	bacter	ricidal	fungi	icidal	
	Candida albicans	suspension test method,	B5.10.2/14			30	60	30	60	30	60	30	60	
		Guidelines for testing	Temperature:			min	min	min	min	min	min	min	min	
		chemical disinfectants for	10 or 20 °C		20	0.25	0.25	0.1	0.1	0.5	0.5	0.2	0.1	
		veterinary medicine (1984)	Exposure	A	10	2.0	0.5	0.5	0.25	3.0	1.0	2.0	1.0	
		by the Committee	time: 5, 15,		20	0.25	0.25	0.1	0.1	0.25	0.25	0.1	0.1	
		"Disinfection in Veterinary	30 and 60 min	В	10	2.0	0.5	0.5	0.25	2.0	0.5	0.25	0.25	
		Medicine" of the German	Interfering	ł		1				1	1	1	1	
		Veterinary Medical	substance:											
		Association e.V. (DVG)	without, or 10											
			% bovine											
			serum, or 1%											
Comiol dilution		Qualitative and quantitative	skimmed milk	Dester		: . / C	: : .							D5 10 2/11
Serial dilution	Staphylococcus aureus	Qualitative and quantitative	1 emperature:	Bacter	lostat	lic/fung	Istatic	enect					25.0/	B5.10.2/11
of Ampholyt	Streptococcus faecium	Suspension test method,	20°C	A baci			5 was	achiev	ed at a			n 01 U	23 %0	
1.0 and 0.004	Proteus mirabilis Proudomonas gomucinosa	chamical diginfactants for	Exposure	(V/V) V		at and 0	1.3 70 ('	$15 + 0^{-1}$	EGOL	2000	with pi	otem id	oau	
1.0 and 0.004	Candida albiaans	votorinory modicing (1084)	tillie. 5 , 15 , 20 and 60 min	after an exposure time of 15 to 30 minutes.										
70 (V/V)	Canalaa albicans	by the Committee	Juterfering	A fungicidal effect occurred at a concentration of 0.06% (V/V)										
		"Disinfection in Veterinary	substance:	without and $0.125 / 0 (v/v)$ with protein load after 50 lillingtes										
		Medicine" of the German	without or 10											
		Veterinary Medical	% hovine											
		Association e V (DVG)	serum											
Serial dilution	Staphylococcus aureus	Qualitative and quantitative	Temperature:	Bacter	iostat	tic/fung	istatic	effect						B5 10 2/12
of Ampholyt	Pseudomonas aeruginosa	suspension test method	20 °C	A bact	ericic	al effe	et occu	rred a	t a con	centrat	ion of	20%	(v/v)	D 5.10.2/12
20 between	Candida albicans	Guidelines for testing	Exposure	withou	it and	30%	(v/v) w	vith pr	otein le	oad aft	er 15 n	ninutes	(,,,,)	
5.0 and		chemical disinfectants for	time: 5 15	exposi	ire 3	0 minut	es exp	osure	to 0.5%	6 (with	out pro	otein lo	oad) or	
0.0625 %		veterinary medicine (1984)	30 and 60 min	to 1.0°	% (wi	th prote	ein load	1) for	30 min	utes w	as suff	iciently	v v	
(v/v)		by the Committee	Interfering	bacter	icidal	(reduct	tion fac	ctor >	log 4).)	,	
		"Disinfection in Veterinary	substance:	A funs	gicida	l effect	was ad	chieve	d at a d	concen	tration	of 0.59	% or	
		Medicine" of the German	without, or 10	0.25%	(v/v)	withou	it and 2	2.0% 0	or 1.0%	ώ (v/v)	TEGO	L 2000) with	
		Veterinary Medical	% bovine	protein	n load	l after a	n expo	sure ti	me of	15 or 3	0 mini	ıtes		
		Association e.V. (DVG)	serum	respec	tively	7.								

AmpholytProduct-type 2, 3, 4April 2015

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
substance			conditions		
Serial dilution of TEGOL 2000 between 1 and 0.0312 % (v/v)	Staphylococcus aureus Streptococcus faecium Proteus mirabilis Pseudomonas aeruginosa Candida albicans	Qualitative suspension test according to the DGHM guideline for the testing and evaluation of chemical disinfection procedures	Temperature: 20 °C Exposure time: 5, 15, 30 and 60 min Protein load: 1 % skimmed milk	A bactericidal effect for <i>S. areus</i> , <i>P. mirabilis</i> and <i>P. aeruginosa</i> was achieved at a concentration of 0.25 % (v/v) TEGOL 2000 with protein load (1% skimmed milk) after an exposure time of 15 minutes, while under the same conditions 0.125% TEGOL 2000 was effective against <i>S. faecium</i> . 30 minutes 0.25% TEGOL 2000 was effective against <i>P. mirabilis</i> and <i>P. aeruginosa</i> and 0.125% against <i>S. aureus</i> and <i>S. faecium</i> . A fungicidal effect (<i>C. albicans</i>) occurred at a concentration of 0.0625 % (v/v) with protein load after 15 and 30 minutes exposure.	B5.10.2/13
Serial dilution of TEGOL 2000 between 2 and 0.25 % (v/v)	Staphylococcus aureus Pseudomonas aeruginosa Candida albicans		Temperature: 10°C Exposure time: 5, 15, 30 and 60 min Protein load: 1 % skimmed milk	A bactericidal effect for <i>P. aeruginosa</i> was achieved at a concentration of 2 % (v/v) TEGOL 2000 with protein load (1% skimmed milk) after an exposure time of 15 minutes, while under the same conditions 0.25% TEGOL 2000 was effective against <i>C. albicans</i> . 30 minutes 0.5% TEGOL 2000 was effective against <i>S. aureus</i> and 0.25% against <i>C. albicans</i>	B5.10.2/14
2.0, 1.0, 0.75, 0.5, 0.25, 0.10 and 0.05 % of Ampholyt 20	Staphylococcus aureus Escherichia coli Proteus mirabilis Pseudomonas aeruginosa	Qualitative suspension test according to the DGHM guideline for the testing and evaluation of chemical disinfection procedures	Temperature: $20 \pm 1^{\circ}C$ Interfering substance: without, or 20 % bovine serum, 0.2%, 1.0% bovine albumin	Under clean conditions all bacteria strains were inactivated at 0.5% Ampholyt 20 after 5 min. Also with 20% bovine serum <i>Escherichia coli</i> , <i>Proteus mirabilis</i> and <i>Pseudomonas aeruginosa</i> were inactivated at 0.5% after 5 min, though <i>Staphylococcus aureus</i> was eliminated at 0.5% after 10 min. With 0.2% bovine albumin all bacteria strains were inactivated at 0.5% Ampholyt 20 after 5 minutes. With 1.0% bovine albumin <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> were inactivated at 0.5% after 5 min, though, <i>Proteus mirabilis</i> and <i>Pseudomonas aeruginosa</i> were inactivated at 0.5% after an exposure time of \geq 20 minutes or with a higher disinfectant concentration.	B5.10.2/15

Ampholyt	Product-type 2, 3, 4	April 2015
----------	----------------------	------------

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
substance			conditions		
0.75 %, 1.5	human rotavirus	Quantitative suspension test	Temperature:	Ampholyt 20 at concentrations of 0.75% and 1.5% showed an	B5.10.2/17
%, 2.0 %			20 °C	efficacy on rota virus (reduction of the titre, $\Delta \log ID_{50}$) after 60	
Ampholyt 20			Exposure	min of exposure. The reduction of recommended $\Delta \log ID_{50}$	
			time: 15 min,	\geq 4.00 is achieved with 2% Ampholyt 20 after 30 min.	
			30 min, 60		
			min		
			Interfering		
			substance: no		
0.75 %	avian influenza virus A	Inactivation tests (micro-	Exposure	After an exposure time of 5 minutes a reduction of the virus titre	B5.10.2/18
Ampholyt 20		procedure) carried out in	time: 5 min,	was measured being 4.25. After 10 minutes no virus could be	
		accordance to	10 min, 15	detected any longer (RF \geq 5.25).	
		Bundesgesundheitsamt	min, 30 min		
		(BGA) and Deutsche	, , , , , , , , , , , , , , , , , , ,		
		Vereinigung zur			
		Bekämpfung der			
		Viruskrankheiten (DVV) –			
		guideline with interfering			
		substances as mentioned in			
		EN 14476 (2005).			

Product-type 2, 3, 4

April 2015

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
substance			conditions		
1% Tego 51	Poxvirus	At room temperature 1 ml	1, 5 and 30	Efficacy of TEGO 51 (1%) on Poxvirus, Herpesvirus,	B5.10.2/19
	Herpesvirus	of TEGO 51 was mixed	min exposure	Orthomyxovirus, Adenovirus and Rhabdovirus is measured by	
	Enterovirus	with 1 ml of the virus stock	time	reduction of the virucidal effect in the test cell line. TEGo 51 is	
	Adenovirus	suspension to be tested.		able to inactivate within one minute over 99 % of the viruses.	
	Rhabdovirus	After each exposure time		Enterovirus are totally resistant and after 30 minutes of contact	
	Orthomyxovirus	the mixture was rapidly		their titre remains equal to the control.	
		diluted to 10 ⁻⁸ in MEM		Summarising the results, it can be recommended to use the	
		with 5 % of inactivated		surface disinfectant TEGO 51 for inactivation of the lipophilic	
		bovine fetal serum. Five		viral groups (Poxvirus, Herpesvirus, Orthomyxovirus,	
		wells of a microtitre plate		Adenovirus and Rhabdovirus) as follows: 1 %, at least 1 min.	
		with a confluent monolayer		The Enterovirus Poliovirus type 1 strain proves absolutely	
		were inoculated with 50 µl		resistant.	
		of the mixture, for 60			
		minutes placed at 37 °C			
		(virus adsorption time)			
		before the inoculums was			
		removed from each well			
		and 0.1 ml medium (MEM			
		or ELH with 5 %			
		inactivated bovine fetal			
		serum) was added. For the			
		incubation the plates were			
		placed at 37 °C in CO ₂			
		incubator.			

Ampholyt	Product-type 2, 3, 4	April 2015
----------	----------------------	------------

Test	Test organism(s)	Test method	Test	Test results: effects, mode of action, resistance	Reference
substance			conditions		
1.0, 0.5 and	Pseudomonas aeruginosa	EN 1040 (2005)	5, 15 and 30	Evidence of inherent biological and yeasticidal activity shown.	B5.10.2/20
0.25 % (v/v)	Staphylococcus aureus	EN 1275 (2005)	min exposure	No evidence of activity against A. niger, therefore fungicidal	
of Ampholyt	Enterococcus	EN 1276 (1997)	time	activity cannot be claimed. Test methods not performed in full	
20	hirae	EN 1650 (1997)		accordance with related EN standards and evidence of errors in	
		EN 13697 (2001)		report.	
	ATCC 10541				
	Escherichia				
	coli				
	ATCC 10536				
	Staphylococcus aureus				
	methycillin resistant				
	(MRSA)				
	ATCC 33592				
	Candida albicans				